Cargando…
The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide
The overexpression of ATP-binding cassette (ABC) transporters is a common cause of multidrug resistance (MDR) in cancers. The intracellular drug concentration of cancer cells can be decreased relative to their normal cell counterparts due to increased expression of ABC transporters acting as efflux...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409168/ https://www.ncbi.nlm.nih.gov/pubmed/32707710 http://dx.doi.org/10.3390/cancers12071963 |
_version_ | 1783568003188654080 |
---|---|
author | Teng, Qiu-Xu Luo, Xiaofang Lei, Zi-Ning Wang, Jing-Quan Wurpel, John Qin, Zuodong Yang, Dong-Hua |
author_facet | Teng, Qiu-Xu Luo, Xiaofang Lei, Zi-Ning Wang, Jing-Quan Wurpel, John Qin, Zuodong Yang, Dong-Hua |
author_sort | Teng, Qiu-Xu |
collection | PubMed |
description | The overexpression of ATP-binding cassette (ABC) transporters is a common cause of multidrug resistance (MDR) in cancers. The intracellular drug concentration of cancer cells can be decreased relative to their normal cell counterparts due to increased expression of ABC transporters acting as efflux pumps of anticancer drugs. Over the past decades, antimicrobial peptides have been investigated as a new generation of anticancer drugs and some of them were reported to have interactions with ABC transporters. In this article, we investigated several novel antimicrobial peptides to see if they could sensitize ABCB1-overexpressing cells to the anticancer drugs paclitaxel and doxorubicin, which are transported by ABCB1. It was found that peptide XH-14C increased the intracellular accumulation of ABCB1 substrate paclitaxel, which demonstrated that XH-14C could reverse ABCB1-mediated MDR. Furthermore, XH-14C could stimulate the ATPase activity of ABCB1 and the molecular dynamic simulation revealed a stable binding pose of XH-14C-ABCB1 complex. There was no change on the expression level or the location of ABCB1 transporter with the treatment of XH-14C. Our results suggest that XH-14C in combination with conventional anticancer agents could be used as a novel strategy for cancer treatment. |
format | Online Article Text |
id | pubmed-7409168 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74091682020-08-26 The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide Teng, Qiu-Xu Luo, Xiaofang Lei, Zi-Ning Wang, Jing-Quan Wurpel, John Qin, Zuodong Yang, Dong-Hua Cancers (Basel) Article The overexpression of ATP-binding cassette (ABC) transporters is a common cause of multidrug resistance (MDR) in cancers. The intracellular drug concentration of cancer cells can be decreased relative to their normal cell counterparts due to increased expression of ABC transporters acting as efflux pumps of anticancer drugs. Over the past decades, antimicrobial peptides have been investigated as a new generation of anticancer drugs and some of them were reported to have interactions with ABC transporters. In this article, we investigated several novel antimicrobial peptides to see if they could sensitize ABCB1-overexpressing cells to the anticancer drugs paclitaxel and doxorubicin, which are transported by ABCB1. It was found that peptide XH-14C increased the intracellular accumulation of ABCB1 substrate paclitaxel, which demonstrated that XH-14C could reverse ABCB1-mediated MDR. Furthermore, XH-14C could stimulate the ATPase activity of ABCB1 and the molecular dynamic simulation revealed a stable binding pose of XH-14C-ABCB1 complex. There was no change on the expression level or the location of ABCB1 transporter with the treatment of XH-14C. Our results suggest that XH-14C in combination with conventional anticancer agents could be used as a novel strategy for cancer treatment. MDPI 2020-07-19 /pmc/articles/PMC7409168/ /pubmed/32707710 http://dx.doi.org/10.3390/cancers12071963 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Teng, Qiu-Xu Luo, Xiaofang Lei, Zi-Ning Wang, Jing-Quan Wurpel, John Qin, Zuodong Yang, Dong-Hua The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide |
title | The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide |
title_full | The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide |
title_fullStr | The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide |
title_full_unstemmed | The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide |
title_short | The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide |
title_sort | multidrug resistance-reversing activity of a novel antimicrobial peptide |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409168/ https://www.ncbi.nlm.nih.gov/pubmed/32707710 http://dx.doi.org/10.3390/cancers12071963 |
work_keys_str_mv | AT tengqiuxu themultidrugresistancereversingactivityofanovelantimicrobialpeptide AT luoxiaofang themultidrugresistancereversingactivityofanovelantimicrobialpeptide AT leizining themultidrugresistancereversingactivityofanovelantimicrobialpeptide AT wangjingquan themultidrugresistancereversingactivityofanovelantimicrobialpeptide AT wurpeljohn themultidrugresistancereversingactivityofanovelantimicrobialpeptide AT qinzuodong themultidrugresistancereversingactivityofanovelantimicrobialpeptide AT yangdonghua themultidrugresistancereversingactivityofanovelantimicrobialpeptide AT tengqiuxu multidrugresistancereversingactivityofanovelantimicrobialpeptide AT luoxiaofang multidrugresistancereversingactivityofanovelantimicrobialpeptide AT leizining multidrugresistancereversingactivityofanovelantimicrobialpeptide AT wangjingquan multidrugresistancereversingactivityofanovelantimicrobialpeptide AT wurpeljohn multidrugresistancereversingactivityofanovelantimicrobialpeptide AT qinzuodong multidrugresistancereversingactivityofanovelantimicrobialpeptide AT yangdonghua multidrugresistancereversingactivityofanovelantimicrobialpeptide |